Skip to content
Screener

Tectonic Therapeutics TECX Investing Cash Flow

Investing Cash Flow at other companies

ALN
Alnylam PharmaceuticalsALNY
-$363.46M-157%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$23.82M-389%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$9.76M+621%
Regenxbio logo
RegenxbioRGNX
$65.93M+147%
Opko Health logo
Opko HealthOPK
$15.54M
Celcuity logo
CelcuityCELC
$34.52M+42.3%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$639.46M+54.6%
Enterprise value$407.46M+219%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Tectonic Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:19 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212016
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net cash used in operating activities(18,413)(13,083)
Cash flows from investing activities:
Purchase of property and equipment(19)(27)
Net cash used in investing activities(19)(27)
Cash flows from financing activities:
Proceeds from the at-the-market offering, net of offering costs1,264
Proceeds from the private placement, net of offering costs177,268
Proceeds from exercise of stock options100972

Item 1. Financial Statements.

FAQ

What is Tectonic Therapeutics's investing cash flow?
Tectonic Therapeutics (TECX) reported investing cash flow of -$19K in Q1 2026.
How has Tectonic Therapeutics's investing cash flow changed year-over-year?
Tectonic Therapeutics's investing cash flow increased by 29.6% year-over-year, from -$27K to -$19K.
What is the long-term trend for Tectonic Therapeutics's investing cash flow?
Over 4 years (2021 to 2025), Tectonic Therapeutics's investing cash flow has grown at a -51.3% compound annual growth rate (CAGR), from -$2.46M to -$138K.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Tectonic Therapeutics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude